文献速递肿瘤 PET/CT放射性药物与辐射防护

靶向整合素αvβ3与CD13的[68Ga]Ga-HX01在健康受试者与恶性肿瘤患者中的I期研究

Phase I study of [68Ga]Ga-HX01 for targeting integrin αvβ3 and CD13 in healthy and malignancy subjects.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-11-29

本研究将靶向整合素αvβ3与CD13的异二聚体PET示踪剂[68Ga]Ga-HX01推进至I期临床,纳入12名健康志愿者(Ia期)和10名恶性肿瘤患者(Ib期)。Ia期分析生物分布、药代动力学、辐射剂量学与安全性,Ib期于注射后30±5和60±5分钟行PET/MR评估安全性与初步诊断价值。结果显示示踪剂主要经肾脏排泄、血液清除快,未观察到严重不良事件,能清晰检出病灶。

要点

  • Ia期12名健康志愿者分低剂量(0.05 mCi/kg)与高剂量(0.1 mCi/kg)组,两剂量组分布代谢相似,肾脏与尿液摄取最高。
  • 消除半衰期T1/2为28.92±3.97分钟,总有效剂量为2.14×10⁻² mSv/MBq。
  • Ib期10名恶性肿瘤患者中[68Ga]Ga-HX01清晰检出病灶,共发现59个摄取程度不一的病灶,检查期间未观察到严重不良事件。

核心结论

  • [68Ga]Ga-HX01被证明是一种具有可靠安全性、良好药代动力学和肿瘤可视化能力的转化型放射性药物。
  • 恶性肿瘤患者的初步结果提示需进一步研究[68Ga]Ga-HX01用于监测恶性肿瘤患者抗血管生成治疗。

研究设计与样本

  • I期临床研究,纳入12名健康志愿者(Ia期)和10名恶性肿瘤患者(Ib期)。
  • Ia期受试者分为低剂量(0.05 mCi/kg)和高剂量(0.1 mCi/kg)组,采集PET/CT图像、血液和尿液样本分析生物分布、药代动力学、辐射剂量学和安全性。
  • Ib期患者于注射后30±5和60±5分钟行PET/MR扫描,评估安全性和初步诊断价值。
  • 临床试验注册号NCT06416774,注册日期2024年5月11日。

主要发现

  • Ia期中[68Ga]Ga-HX01在两个剂量组分布和代谢相似,肾脏和尿液摄取最高,具有快速肾脏排泄和血液清除,消除半衰期T1/2为28.92±3.97分钟。
  • 总有效剂量为2.14×10⁻² mSv/MBq。
  • Ib期中[68Ga]Ga-HX01清晰检出每名患者的病灶,共发现59个摄取程度不一的病灶。
  • 安全性评价中检查期间未观察到严重不良事件。

临床怎么用

  • 原文结论指出[68Ga]Ga-HX01具有可靠安全性、良好药代动力学和肿瘤可视化能力,恶性肿瘤患者的初步结果提示需进一步研究其用于监测抗血管生成治疗。

局限性

  • 原文结论指出恶性肿瘤患者的初步结果需进一步研究[68Ga]Ga-HX01用于监测恶性肿瘤患者抗血管生成治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Noninvasive angiogenesis visualization is essential for evaluating tumor proliferation, progression, invasion, and metastasis. This study aimed to translate the heterodimeric PET tracer [68Ga]Ga-HX01, which targets integrin αvβ3 and CD13 in neovascularization, into phase I clinical study. METHODS: This study enrolled 12 healthy volunteers (phase Ia) and 10 patients with malignant tumors (phase Ib). The subjects in phase Ia were divided into low-dose (0.05 mCi/kg) and high-dose (0.1 mCi/kg) groups. For phase Ia subjects, PET/CT images, blood and urine samples were collected to analyze the biodistribution, pharmacokinetics, radiation dosimetry, and safety of [68Ga]Ga-HX01. For phase Ib patients, PET/MR scans were performed at 30 ± 5 and 60 ± 5 min after injection. The safety and preliminary diagnostic value of [68Ga]Ga-HX01 were assessed. RESULTS: In phase Ia study, [68Ga]Ga-HX01 was distributed and metabolized similarly in two dosage groups as the highest accumulations in kidneys and urine. It possessed quick renal excretion and blood clearance with an elimination half-life (T1/2) of 28.92 ± 3.97 min. The total effective dose was 2.14 × 10- 2 mSv/MBq. In phase Ib study, [68Ga]Ga-HX01 clearly detected the lesions per patient, and found a total of 59 lesions with varying uptake levels. For safety evaluation, no serious adverse events were observed during the examination. CONCLUSION: [68Ga]Ga-HX01 has proved to be a translational radiopharmaceutical with reliable security, favorable pharmacokinetics, and the ability to visualize tumors. The preliminary results in malignancy patients warrant further investigation of [68Ga]Ga-HX01 in monitoring antiangiogenic therapy of patients with malignancies. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT06416774. Registered 11 May, 2024.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Zhang X, Fang H, Yang B, et al. Phase I study of [68Ga]Ga-HX01 for targeting integrin αvβ3 and CD13 in healthy and malignancy subjects. Eur J Nucl Med Mol Imaging. 2024. PMID: 39609274. doi:10.1007/s00259-024-07002-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。